Janvier Labs Acquires Yecuris


Janvier Labs, a portfolio company of MxEP, acquisition of Yecuris


Janvier Labs, a subsidiary of the Janvier Group and portfolio company of Mérieux Equity Partners ("MxEP"), has acquired the Yecuris Corporation (“Yecuris”). Terms of the transaction were not disclosed.

Baird served as exclusive financial advisor to Janvier Labs on this transaction.


As an international player in the field of biomedical research, the Janvier Group is a reference in terms of research models and preclinical services. Founded in 1960, the Janvier Group is one of the world leaders, recognized for the quality of its research models and associated services which are delivered in compliance with the standards among the highest in the world market. Historically focused on research models with its subsidiary Janvier Labs, which relies on the largest and most modern production site in Europe, Janvier Group is now an established player in preclinical services with its subsidiaries in France and internationally. Today, the Janvier Group operates throughout Europe and internationally with more than 3,500 customers. The Janvier Group is headquartered in Saint-Berthevin, France.

Mérieux Equity Partners is an AMF-accredited management company dedicated to equity investments in the Healthcare and Nutrition sectors. MxEP actively supports entrepreneurs and companies with differentiated products and services, giving them privileged access to its sector expertise and international network. MxEP currently manages c.€1.5bn AUM. MxEP is headquartered in Lyon, France.

Yecuris was founded in 2007 as a start-up company based on technology developed in the laboratory of Dr. Markus Grompe at Oregon Health and Science University. Yecuris has grown its proprietary FRG liver-humanized mouse model into a globally recognized name. Yecuris’ products and services help biotechnology and pharmaceutical companies active in the fields of Gene Therapy, Infectious Disease, Metabolic Disease and Liver Disease develop next-generation medicines to treat human disease. Yecuris’ singular purpose is to deliver actionable results that clients can depend on to make critical decisions in their drug development programs. Yecuris is headquartered in Portland, Oregon.

Janvier Labs, a portfolio company of MxEP, acquisition of Yecuris

January 2024
Janvier Labs
M&A - Buyside
Pharmaceutical Services
Target Geography
North America
Acquiror Geography